These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 11797710)

  • 21. FDA perspectives on supplement use by patients on antithrombotic therapy.
    Kim MJ
    Thromb Res; 2005; 117(1-2):197-200; discussion 201-7. PubMed ID: 16188297
    [No Abstract]   [Full Text] [Related]  

  • 22. [Regulatory aspects of the drug authorization for children. USA, Europe and Germany].
    Franken A
    Pharm Unserer Zeit; 2009; 38(1):44-9. PubMed ID: 19132678
    [No Abstract]   [Full Text] [Related]  

  • 23. Realizing two-tiered innovation policy through drug regulation.
    Ridgway WE
    Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
    [No Abstract]   [Full Text] [Related]  

  • 24. Trends in antimicrobial drug development: implications for the future.
    Spellberg B; Powers JH; Brass EP; Miller LG; Edwards JE
    Clin Infect Dis; 2004 May; 38(9):1279-86. PubMed ID: 15127341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A survey of developments in food and drug law from July 1998 to November 1999.
    Littlefield N; Hada NR
    Food Drug Law J; 2000; 55(1):35-56. PubMed ID: 12296348
    [No Abstract]   [Full Text] [Related]  

  • 26. Revision of the requirements for live vaccine processing; confirmation of effective date. Direct final rule; confirmation of effective date.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Mar; 73(46):12262-3. PubMed ID: 18464339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Communicating with the FDA: the "third rail" of a new model for drug development.
    Stanski DR; Orloff JJ
    J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
    [No Abstract]   [Full Text] [Related]  

  • 28. Drugs and vaccines for the common defense: refining FDA regulation to promote the availability of products to counter biological attacks.
    Javitt GH
    J Contemp Health Law Policy; 2002; 19(1):37-116. PubMed ID: 12733223
    [No Abstract]   [Full Text] [Related]  

  • 29. Regulating the fate of pharmaceutical drugs: a new prescription for the environment.
    Nidel CT
    Food Drug Law J; 2003; 58(1):81-101. PubMed ID: 12739585
    [No Abstract]   [Full Text] [Related]  

  • 30. FDA perspectives on supplement use by patients on antithrombotic therapy: dietary supplement regulatory overview.
    Woo JJ
    Thromb Res; 2005; 117(1-2):193-6; discussion 201-7. PubMed ID: 16253311
    [No Abstract]   [Full Text] [Related]  

  • 31. In U.S., biosimilars still await FDA decision.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Apr; 98(7):435. PubMed ID: 16595775
    [No Abstract]   [Full Text] [Related]  

  • 32. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDA reform: new Senate bill. Food and Drug Administration.
    James JS
    AIDS Treat News; 1995 Nov; (no 235):7-8. PubMed ID: 11363048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plan BTC: the case for a third class of drugs in the United States.
    Healey D
    Food Drug Law J; 2008; 63(1):375-89. PubMed ID: 18561465
    [No Abstract]   [Full Text] [Related]  

  • 35. Future drugs that will be lifesavers for the industry too.
    Bylinsky G
    Fortune; 1976 Dec; 94(6):153-6, 158, 162. PubMed ID: 1028679
    [No Abstract]   [Full Text] [Related]  

  • 36. Report of the Task Force on the future of OTC drugs.
    Collins DE
    Food Drug Law J; 2000; 55(1):27-31. PubMed ID: 12269359
    [No Abstract]   [Full Text] [Related]  

  • 37. Risks, regulation, and rewards in new drug development in the United States.
    DiMasi JA
    Regul Toxicol Pharmacol; 1994 Apr; 19(2):228-35. PubMed ID: 8041920
    [No Abstract]   [Full Text] [Related]  

  • 38. FDA notifications. Pediatric formulation of lamivudine approved.
    AIDS Alert; 2008 Mar; 23(3):32-3. PubMed ID: 18663776
    [No Abstract]   [Full Text] [Related]  

  • 39. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lawsuits anticipated on generic biologicals front.
    Fox JL
    Nat Biotechnol; 2003 Jul; 21(7):721-2. PubMed ID: 12833078
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.